secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001104659-22-086135
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q2 revenue up 40% to $198.2M; raises FY2022 guidance to $805M-$825M
--------------------------------------------------------------------------

- Total revenue $198.2M (+39.6% YoY); product revenue $194.6M (+39.3%).
- Tests processed ~499,900, up 33% YoY; net loss $145.2M ($1.50/share) vs $116.0M ($1.32).
- 2022 revenue guidance raised to $805M-$825M; gross margin ~46%-48%.
- Cash & investments $638.7M, down from $914.5M at Dec 31, 2021; net cash consumption expected $370M-$400M.
- Selected for UnitedHealthcare Preferred Lab Network; Medicare coverage for Signatera in muscle invasive bladder cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465922086135/0001104659-22-086135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465922086135/tm2222580d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-086135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer